168 related articles for article (PubMed ID: 7022593)
1. Prostate cancer. Endocrine and cytotoxic therapy.
Smith PH
Recent Results Cancer Res; 1981; 78():154-72. PubMed ID: 7022593
[No Abstract] [Full Text] [Related]
2. Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense?
Schulman CC; Wildschutz TP
Acta Urol Belg; 1996 May; 64(2):57-61. PubMed ID: 8701814
[No Abstract] [Full Text] [Related]
3. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
[No Abstract] [Full Text] [Related]
4. [Hormonal treatments of prostate cancer].
Kuhn JM
Rev Prat; 1990 Nov; 40(25):2357-62. PubMed ID: 2124721
[No Abstract] [Full Text] [Related]
5. The evolving role of estrogen therapy in prostate cancer.
Oh WK
Clin Prostate Cancer; 2002 Sep; 1(2):81-9. PubMed ID: 15046698
[TBL] [Abstract][Full Text] [Related]
6. The patient, disease status, and treatment options for prostate cancer: stages D1 and D2.
Schmidt JD
Prostate; 1983; 4(5):493-501. PubMed ID: 6351040
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced cancer of the prostate.
Chisholm GD
Semin Surg Oncol; 1985; 1(1):38-55. PubMed ID: 3887539
[TBL] [Abstract][Full Text] [Related]
8. Newer approaches to androgen deprivation therapy in prostate cancer.
Pitts WR
Urology; 2003 Apr; 61(4):882. PubMed ID: 12670593
[No Abstract] [Full Text] [Related]
9. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
10. Distant disease.
Newling DW; McLeod D; Soloway M; Di Silverio F; Smith P
Cancer; 1992 Jul; 70(1 Suppl):365-7. PubMed ID: 1600496
[No Abstract] [Full Text] [Related]
11. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
12. [Significance of neoadjuvant therapy for prostate cancer].
Okada K; Hachiya T
Nihon Hinyokika Gakkai Zasshi; 1997 Sep; 88(9):769-77. PubMed ID: 9364842
[No Abstract] [Full Text] [Related]
13. Initiation of LHRH monotherapy for prostate cancer.
Milsted RA
Prog Clin Biol Res; 1989; 303():69-74. PubMed ID: 2528742
[No Abstract] [Full Text] [Related]
14. Endocrine treatment: expected duration stage by stage.
Schröder FH
Prostate Suppl; 2000; 10():26-31. PubMed ID: 11056490
[No Abstract] [Full Text] [Related]
15. Advanced prostate cancer. Hormonal treatment.
de la Haba-Rodríguez J
Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
[No Abstract] [Full Text] [Related]
16. [Hormonal treatment of advanced cancer of the prostate].
de Leval J
Rev Med Liege; 1991 Nov; 46(11):577-82. PubMed ID: 1754776
[No Abstract] [Full Text] [Related]
17. Principles of endocrine manipulation in the treatment of prostatic cancer.
Neumann F
Prog Clin Biol Res; 1985; 185A():73-98. PubMed ID: 3898136
[No Abstract] [Full Text] [Related]
18. The role of diethylstilbestrol in the treatment of prostate cancer.
Malkowicz SB
Urology; 2001 Aug; 58(2 Suppl 1):108-13. PubMed ID: 11502463
[TBL] [Abstract][Full Text] [Related]
19. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
Scalliet P
Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
[No Abstract] [Full Text] [Related]
20. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
Boccardo F; Pace M
In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
